ProMIS Neurosciences Presents at the 2022 American Academy of Neurology Annual Meeting

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it has presented at the  American Academy of  Neurology (AAN) Annual Meeting held at the Washington State Convention Center in Seattle, April 2-7, 2022.

 

Dr. Beibei Zhao delivered a poster presentation entitled: โ€œRACK1 Knockdown Alleviates TDP-43-Associated Global Translational Suppression in vitro and Neurodegeneration in vivoโ€ during Session P3: Neuromuscular Disease: Amyotrophic Lateral Sclerosis 3, on Saturday, April 2nd. 

 

The receptor of activated C-kinase 1 (RACK1) is a well-conserved protein with more than 100 recognized activities. Co- aggregation of RACK1 with TDP-43 inclusions has been observed in sporadic ALS suggesting that it may be part of a pathogenic interactome involving the two proteins.

 

The poster addresses whether knockdown of RACK1 in mature cells may be beneficial against TDP-43 related pathology in cultured cells and in a living organism, the Drosophila fruit fly.  The results are consistent with the existence of a pathogenic interaction between TDP-43 and RACK1 in misfolded aggregates and support targeting of RACK1 to alleviate TDP-43 proteinopathy.

 

The poster abstract is available on the AAN website here. Dr. Zhaoโ€™s poster presentation will be available on the ProMIS website (www.promisneurosciences.com) at the conclusion of the meeting.

 

For more information about the meeting please consult the AAN annual meeting website.

  

ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing therapeutics selectively targeting toxic misfolded oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimerโ€™s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinsonโ€™s disease (PD). The Companyโ€™s proprietary target discovery engine is based on the use of two complementary computational modeling techniques. The Company applies its molecular dynamics, computational discovery platform -ProMISโ„ข and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF

 

www.promisneurosciences.com


Hot this week

The End of the Due Diligence Bottleneck? Valuticoโ€™s โ€œDone Diligenceโ€ Arrives

Valutico Launches AI Platform to Revolutionise Due Diligence. The financial...

Justice for Hind: On Her 7th Birthday, A Name, A Crime, and the Deafening Silence of the West

On what should have been her seventh birthday, little...

A Century of Israeli Massacres: Palestineโ€™s Unyielding Resistance

The mass slaughter unfolding in Gaza today is not...

Topics

Related Articles

Popular Categories

spot_imgspot_img